The findings revealed a decrease in the H-score of GDF11 in patients with tumor size ≥ 2 cm, pathologic T3 + T4 stages, AJCC III–IV stages, Ki67 ≥ 14% status, HER2-negative, and the molecular tumor subtypes, including luminal B HER2-negative and triple-negative (all p-values < 0.05, Table 2). This evidence concerns the gene ERBB2 and neoplasm.